No Data
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
GSK, CureVac MRNA Flu Shot Reaches Late-stage Studies
Express News | CureVac NV Says : CureVac Partner GSK Announces Positive Phase 2 Data From Seasonal Influenza Mrna Vaccine Program
CureVac Unveils Promising Glioblastoma Vaccine Data
Deutsche Bank Maintains CureVac(CVAC.US) With Hold Rating, Cuts Target Price to $3.9
Deutsche Bank analyst Emmanuel Papadakis maintains $CureVac(CVAC.US)$ with a hold rating, and adjusts the target price from $5 to $3.9.According to TipRanks data, the analyst has a success rate of 57.